VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here’s what investors need to know before the announcement.
Analysts estimate that VistaGen Therapeutics will report an earnings per share (EPS) of $-0.68.
VistaGen Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here’s a look at VistaGen Therapeutics’s past performance and the resulting price change:
| Quarter | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| EPS Estimate | -2.1 | -2.1 | ||
| EPS Actual | -0.94 | -1.61 | -1.5 | -2.4 |
| Price Change % | -14.57% | 4.65% | -28.68% | 24.62% |
Stock Performance
Shares of VistaGen Therapeutics were trading at $3.475 as of November 07. Over the last 52-week period, shares are down 19.36%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for VistaGen Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
